A Pilot Trial of Lithium in Inclusion Body Myositis (IBM)
Trial Status
Open for Enrollment
What is the Purpose of this Study?
There is currently no effective treatment for IBM and its pathogenesis
remains uncertain. This study is designed to test the hypothesis that treatment
of patients with IBM with Lithium can improve muscle strength and reduce
the markers of disease activity believed to be important in the disease
pathogenesis.
Who is Eligible to Participate?
Patients diagnosed with Inclusion Body Myositis above the age of 30 who
have adequate muscle function for quantitative muscle testing. Patients
must also meet all other inclusion and exclusion criteria explained in further
detail by study coordinator
What is involved in this Study?
This is an open label trial of the effects of Li on muscle strength. Procedures
consist of a baseline muscle biopsy, and blood work. Two weeks later
patients are given Li at 300mg/d every month. Every
two weeks patients return to for study visits for EKGs, Li level labs,
questionnaires, and muscle strength testing. At the end of the study,
patients will receive another muscle biopsy.
How long is the Study?
It is approximately 6 months long.
For More Information Contact: Nicole C. Hank, MHSM, study coordinator, at
602-258-3354 ext 137 or nhank@pnal.net or call the Main line at 602-258-3354
IBM Symptoms
IBM Cause
IBM Cure
IBM Treatment
|
